283 related articles for article (PubMed ID: 24550325)
1. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
[TBL] [Abstract][Full Text] [Related]
2.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
3.
Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Zhanel GG
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373806
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
[TBL] [Abstract][Full Text] [Related]
5. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
[TBL] [Abstract][Full Text] [Related]
6. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
[TBL] [Abstract][Full Text] [Related]
8. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
12.
Fleischmann WA; Greenwood-Quaintance KE; Patel R
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712206
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
14. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Zhang Y; Kashikar A; Bush K
J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
[TBL] [Abstract][Full Text] [Related]
16. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
